SEC Form 4 · accession 0000899243-17-002388
Wave Life Sciences, Inc. · WVE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Adrian Rawcliffe
Director
Period of report
Feb 1, 2017
Accepted (ET)
Feb 1, 2017 · 6:39 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001631574
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Share Option (right to buy)F1 | $28.80 | Feb 1, 2017 | A | 18,000 | A | — | Feb 1, 2022 | Ordinary Shares | 18,000 | 18,000 | D |
Explanation of responses
- F1The reporting person was granted this option pursuant to the Non-Employee Director Compensation Policy.The option vests as to 25% of the shares on February 1, 2018 and vests as to an additional 2.0833% of the shares monthly thereafter until February 1, 2021.